ChinaTuberculosis profile
Population  2014 1 369 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 38 (37–40) 2.8 (2.7–2.9)
Mortality (HIV+TB only) 0.7 (0.53–0.9) 0.05 (0.04–0.07)
Prevalence  (includes HIV+TB) 1 200 (1 100–1 400) 89 (78–102)
Incidence  (includes HIV+TB) 930 (860–1 000) 68 (63–73)
Incidence (HIV+TB only) 13 (11–16) 0.98 (0.79–1.2)
         
Case detection, all forms (%) 88 (82–95)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 5.7 (4.5–7) 26 (22–30)
MDR-TB cases among notified pulmonary
TB cases
43 000 (34 000–53 000) 8 200 (6 900–9 500)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 235 704   25 125
Pulmonary, clinically diagnosed 526 106    
Extrapulmonary 32 348    
       
Total new and relapse 819 283    
Previously treated, excluding relapses 6 872    
Total cases notified 826 155    
Among 819 283 new and relapse cases:
4 164 (<1%) cases aged under 15 years; male:female ratio: 2.3
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 45 664 (19%) 17 210 (54%) 62 874
Laboratory-confirmed RR-/MDR-TB cases     5 807
Patients started on MDR-TB treatment ***     2 846
TB/HIV 2014 Number (%)
TB patients with known HIV status 343 515 (42)
HIV-positive TB patients 5 309 (2)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 3 675 (69)
HIV-positive people screened for TB 423 254  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (95) 841 999
Previously treated cases, excluding relapse, registered in 2013 (90) 7 847
HIV-positive TB cases, all types, registered in 2013 (82) 4 649
RR-/MDR-TB cases started on second-line treatment in 2012 (42) 1 906
XDR-TB cases started on second-line treatment in 2012 (13) 115
Laboratories 2014  
Smear (per 100 000 population) 0.2
Culture (per 5 million population) 6.7
Drug susceptibility testing (per 5 million population) 1.5
Sites performing Xpert MTB/RIF 654
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 340
% Funded domestically 90%
% Funded internationally 2%
% Unfunded 8%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-04-30 Data: www.who.int/tb/data